Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 9/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | PYGL | P06737 | 2/20 | 0.38 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPY1R | P25929 | 1/20 | 0.36 |
| ▸ | NPY2R | P49146 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3690868 | 1.00 | TLR4 (0.73) | TLR4KMT2AHPGDNPC1RAB9A | |
| SCHEMBL722368 | 1.00 | TLR4 (0.73) | TLR4KMT2AHPGDNPC1RAB9A | |
| SCHEMBL27592234 | 0.97 | TLR4 (0.73) | TLR4KMT2AHPGDNPC1RAB9A | |
| SCHEMBL27592449 | 0.93 | TLR4 (0.72) | TLR4KMT2AHPGDNPC1RAB9A | |
| SCHEMBL28159349 | 0.88 | TLR4 (0.58) | TLR4NPC1RAB9AMRGPRX1ACLY | |
| SCHEMBL6229405 | 0.88 | TLR4 (0.58) | TLR4KMT2AHPGDNPC1RAB9A | |
| SCHEMBL872918 | 0.88 | TLR4 (0.58) | TLR4NPC1RAB9AMRGPRX1ACLY | |
| SCHEMBL16950256 | 0.88 | TLR4 (0.66) | TLR4KMT2ANPC1RAB9AMRGPRX1 | |
| SCHEMBL6053336 | 0.86 | TLR4 (0.61) | TLR4KMT2ANPC1RAB9AACLY | |
| SCHEMBL13911749 | 0.86 | TLR4 (0.56) | TLR4NPC1RAB9AMRGPRX1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960416-B2 | Oil-in-water emulsion of a 1-carboxylate-6-arylsulfamoyl cyclohexene and synthetic and naturally occurring phospholipids; nitric oxide or cytokine prodution inhibitors; cardiovascular disorders, autoimmune dieseases, septic shock; improved stability during autoclave sterilization | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | claimed |
| US-7247653-B2 | Pharmaceutical composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-24 | — | — | US | claimed |
| EP-1254659-B1 | STABLE EMULSION COMPOSITIONS | TAKEDA PHARMACEUTICAL (JP) | 2006-11-15 | — | — | EP | claimed |
| US-7105572-B2 | Stable emulsion compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-09-12 | — | — | US | claimed |
| US-20050272701-A1 | Pharmaceutical composition | ASAKAWA NAOKI | 2005-12-08 | — | — | US | claimed |
| US-6951885-B2 | Pharmaceutical composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-04 | — | — | US | claimed |
| EP-1524263-A1 | prodrugs containing cycloalkene derivatives | Takeda Pharmaceutical Company Limited (JP) | 2005-04-20 | — | — | EP | claimed |
| EP-1063228-B1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND USE | TAKEDA PHARMACEUTICAL (JP) | 2005-01-19 | — | — | EP | claimed |
| US-20040253276-A1 | Stable emulsion composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-16 | — | — | US | claimed |
| EP-1420783-A1 | STABLE EMULSION COMPOSITION | Takeda Chemical Industries, Ltd. (JP) | 2004-05-26 | — | — | EP | claimed |
| US-20030216475-A1 | Pharmaceutical composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-11-20 | — | — | US | claimed |
| US-20030212114-A1 | Stable emulsion compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-11-13 | — | — | US | claimed |
| EP-1310248-A1 | PHARMACEUTICAL COMPOSITION | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | claimed |
| WO-2003013513-A1 | STABLE EMULSION COMPOSITION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-02-20 | — | — | WO | claimed |
| US-6495604-B1 | SUCH AS D-ETHYL-6-(N-(2,4-DIFLUOROPHENYL)SULFAMOYL)-1-CYCLOHEXENE-1-CARBOXYLATE FOR INHIBITING NITRIC OXIDE AND/OR CYTOKINE PRODUCTION; FOR PREVENTING OR TREATING CARDIAC DISEASE, AUTOIMMUNE DISEASE OR SEPTIC SHOCK | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-12-17 | — | — | US | claimed |
| EP-1254659-A1 | STABLE EMULSION COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2002-11-06 | — | — | EP | claimed |
| EP-1063228-A1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2000-12-27 | — | — | EP | claimed |
| US-20160166526-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-16 | — | — | US | disclosed |
| EP-1254659-A1 | STABLE EMULSION COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
| EP-1063228-A1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2000-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212114-A1 | Stable emulsion compositions | AHR, NR1H2, NR1H3 | TLR4 2050/4885KMT2A 767/4885HPGD 1374/4885 |
| US-20050272701-A1 | Pharmaceutical composition | CEL, HSD17B7, ABCG2 | TLR4 2497/4885KMT2A 4682/4885HPGD 896/4885 |
| US-20160166526-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | PMP22, GAP43, NGF | TLR4 2222/4885KMT2A 3281/4885HPGD 1096/4885 |
| US-20040253276-A1 | Stable emulsion composition | PHOSPHO1, SGMS1, SGMS2 | TLR4 3985/4885KMT2A 3252/4885HPGD 3392/4885 |
| US-20030216475-A1 | Pharmaceutical composition | ARRB1, ADRA1B, ADRB1 | TLR4 2126/4885KMT2A 4037/4885HPGD 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.